A detailed history of Silverarc Capital Management, LLC transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 655,515 shares of ALGS stock, worth $386,753. This represents 0.22% of its overall portfolio holdings.

Number of Shares
655,515
Previous 668,512 1.94%
Holding current value
$386,753
Previous $441,000 45.58%
% of portfolio
0.22%
Previous 0.14%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$0.64 - $1.13 $8,318 - $14,686
-12,997 Reduced 1.94%
655,515 $642,000
Q4 2023

Feb 14, 2024

BUY
$0.56 - $0.8 $20,510 - $29,300
36,625 Added 5.8%
668,512 $441,000
Q1 2023

May 15, 2023

BUY
$0.87 - $2.11 $549,741 - $1.33 Million
631,887 New
631,887 $549,000
Q2 2022

Jul 25, 2022

BUY
$1.04 - $2.14 $49,642 - $102,148
47,733 Added 447.82%
58,392 $71,000
Q1 2022

May 13, 2022

BUY
$2.08 - $12.2 $22,170 - $130,039
10,659 New
10,659 $23,000

Others Institutions Holding ALGS

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $23.4M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.